MESO Q1 2022 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+178.8% YoY

Gross Profit

-$13M-369.3% margin

Operating Income

-$19M-534.4% margin

Net Income

-$23M-630.1% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+80.1%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$722M

Total Liabilities

$162M

Stockholders' Equity

$560M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$1M	+178.8%
Gross Profit	-$13M	-$27M	+51.0%
Operating Income	-$19M	-$36M	+46.0%
Net Income	-$23M	-$25M	+7.7%